Signaturefd LLC Has $43,000 Holdings in Recursion Pharmaceuticals, Inc. $RXRX

Signaturefd LLC cut its holdings in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 25.6% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 8,548 shares of the company’s stock after selling 2,942 shares during the quarter. Signaturefd LLC’s holdings in Recursion Pharmaceuticals were worth $43,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. AlphaQuest LLC acquired a new position in shares of Recursion Pharmaceuticals in the first quarter valued at $36,000. GAMMA Investing LLC raised its stake in shares of Recursion Pharmaceuticals by 39.0% in the first quarter. GAMMA Investing LLC now owns 7,224 shares of the company’s stock valued at $38,000 after purchasing an additional 2,026 shares in the last quarter. San Luis Wealth Advisors LLC acquired a new position in shares of Recursion Pharmaceuticals in the first quarter valued at $54,000. ADG Wealth Management Group LLC acquired a new position in shares of Recursion Pharmaceuticals in the first quarter valued at $55,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in shares of Recursion Pharmaceuticals in the first quarter valued at $57,000. 89.06% of the stock is currently owned by institutional investors and hedge funds.

Recursion Pharmaceuticals Price Performance

Recursion Pharmaceuticals stock opened at $5.53 on Tuesday. The business’s 50-day simple moving average is $5.09 and its 200 day simple moving average is $5.12. The stock has a market cap of $2.40 billion, a price-to-earnings ratio of -3.11 and a beta of 0.91. Recursion Pharmaceuticals, Inc. has a 12-month low of $3.79 and a 12-month high of $12.36. The company has a quick ratio of 3.58, a current ratio of 3.58 and a debt-to-equity ratio of 0.02.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings results on Tuesday, August 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.06). The firm had revenue of $19.10 million during the quarter, compared to the consensus estimate of $15.38 million. Recursion Pharmaceuticals had a negative net margin of 1,004.91% and a negative return on equity of 76.09%. Recursion Pharmaceuticals’s revenue was up 33.3% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.40) EPS. As a group, research analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

Insider Transactions at Recursion Pharmaceuticals

In related news, insider Najat Khan sold 36,599 shares of the firm’s stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $5.52, for a total value of $202,026.48. Following the transaction, the insider owned 668,197 shares in the company, valued at $3,688,447.44. This trade represents a 5.19% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 8.43% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research analysts recently commented on RXRX shares. Weiss Ratings restated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research note on Saturday, September 27th. Morgan Stanley began coverage on Recursion Pharmaceuticals in a report on Thursday, July 3rd. They set an “equal weight” rating and a $5.00 target price on the stock. Finally, Needham & Company LLC restated a “buy” rating and set a $8.00 target price on shares of Recursion Pharmaceuticals in a report on Thursday, September 11th. Two analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $7.25.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.